National and Kapodistrian University of Athens
Μελέτη μηχανισμών αντίστασης του anti-PD-1 σε ασθενείς με μεταστατικό μελάνωμα
Abstract
dc:descriptionImmune checkpoint inhibitors (ICIs) have significantly improved outcomes in melanoma by enhancing adaptive immunity, but not all patients benefit equally. While some experience early relapses, others maintain long-term responses, even after stopping treatment. To uncover cellular and molecular markers in the blood that may distinguish advanced (stage III) from metastatic (stage IV) melanoma and predict immune escape mechanisms, we analyzed 100 consecutive patients diagnosed with stage III/IV melanoma who were about to begin ICI therapy. Before initiating treatment, all patients underwent multiparameter flow cytometry and immune cell isolation using standard conjugated antibodies. Based on recurrence-free or progression-free survival (RFS/PFS), we retrospectively selected patients with the most distinct clinical outcomes. Specifically, we focused on two subgroups — seven strong responders and seven non-responders — and conducted bulk RNA sequencing (RNA-seq) of their circulating CD4+ T cells. We used differential expression analysis (DEA) and Gene Ontology (GO) enrichment to identify gene expression differences and related pathways, comparing stage III vs. IV disease and long-term vs. early non-responders.Although the overall number of circulating immune cells was similar across groups, transcriptomic analyses revealed distinct gene expression profiles. There were 189 vs. 92 differentially expressed genes (DEGs) in stage IV vs. III patients, and 101 vs. 47 DEGs in early progressors vs. long-term responders. These genes were associated with specific biological pathways. In metastatic cases (stage IV), upregulated pathways included: Inflammatory response (e.g., ADGRE5/2, CYBA, GRN, HMOX1, IRF5, ITGAM); Adaptive immunity (e.g., CD1C, CD74,CYBB, NCF2, S100A8/9, BCL3); T-cell activation (e.g., BCL3, CD1C, CD74, FCER1G, FGL2) and Lipid metabolism and catabolism (e.g., ARF3, GPX1, CTSA, PNPLA2, ABHD4). In early ICI non-responders, key upregulated pathways included: Immune effector processing (e.g., HLA-DQA1/DQB1, HLA-DRA, HLA-DRB1/DRB5, NKG7, TYROBP); PD-1 signaling (e.g., HLA-DQA1/DQB1, HLA-DRA, HLA-DRB1/DRB5); Interferon signaling (e.g., HLA-DQA1/DQB1, HLA-DRA, HLA-DRB1/DRB5, NCAM1, IFITM3); Positive regulation of T-cell activation (e.g., BCL6, HLA-DQA1/DQB1, HLA-DRA, HLA-DRB1/DRB5, HAVCR2), and CD28 co-stimulation (e.g., HLA-DQA1/DQB1, HLA-DRA, HLA-DRB1/DRB5), all indicative of immune dysregulation or exhaustion. Our findings suggest that specific gene expression patterns and immune-related pathways in peripheral CD4+ T cells can help predict melanoma stage and resistance to immunotherapy.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Palli, Eleni
- Πάλλη, Ελένη
Subjects
dc:subject × 20- CD4+ T λεμφοκύτταρα
- Αναστολείς σημείων ελέγχου
- Μελάνωμα
- Ανοσοφαινοτύπιση και μεταγραφικές υπογραφές
- Ανταπόκριση και αντίσταση στην ανοσοθεραπεία
- CD4+ T lymphocytes
- Immune checkpoint inhibitors
- Melanoma
- Immunophenotyping and transcriptomic signatures
- Response and resistance to immunotherapy
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ανοσολογία
- Κλινική Ιατρική
- Ογκολογία
- Basic Medicine
- Medical and Health Sciences
- Immunology
- Clinical Medicine
- Oncology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/60914